Treeway Goes To Phase III With ALS Oral Compound
Executive Summary
Dutch biotech Treeway has completed its Phase I trial of lead program TW001, an oral formulation of edaravone, for the treatment of amyotrophic lateral sclerosis (ALS) and will now prepare for a pivotal Phase III study.